SecBot SecBot
SECBOTREPLAY Home › Report › ARMP

ARMP · Q3 GAAP net income $54.9M

Armata Pharmaceuticals, Inc. · PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET

Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24) diluted EPS), driven by a $69.6M non-cash gain from convertible loan fair value change. Operating loss narrowed to $7.4M from $7.8M a year ago. The company is preparing for a Phase 3 study of AP-SA02, which received FDA Breakthrough Therapy designation, and received $3.7M in non-dilutive DoW funding. Consensus EPS of $(0.56) was not met on a GAAP basis; the diluted loss per share of $(0.24) compares to a consensus estimate of $(0.56), representing a beat of 57.1%.

  • Q3 2026 net income $54.9M vs net loss $(26.7M) in Q3 2025, driven by $69.6M gain from convertible loan fair value change
  • Diluted EPS $(0.24) vs consensus $(0.56), beat of 57.1%
  • Operating loss improved to $7.4M from $7.8M in Q3 2025
  • Grant and award revenue $3.2M, up from $1.2M in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access